Cytek Biosciences Balance Sheet Health
Financial Health criteria checks 5/6
Cytek Biosciences has a total shareholder equity of $392.6M and total debt of $3.4M, which brings its debt-to-equity ratio to 0.9%. Its total assets and total liabilities are $492.1M and $99.5M respectively.
Key information
0.9%
Debt to equity ratio
US$3.42m
Debt
Interest coverage ratio | n/a |
Cash | US$270.09m |
Equity | US$392.61m |
Total liabilities | US$99.45m |
Total assets | US$492.07m |
Recent financial health updates
Recent updates
Financial Position Analysis
Short Term Liabilities: 8EQ's short term assets ($388.6M) exceed its short term liabilities ($55.6M).
Long Term Liabilities: 8EQ's short term assets ($388.6M) exceed its long term liabilities ($43.9M).
Debt to Equity History and Analysis
Debt Level: 8EQ has more cash than its total debt.
Reducing Debt: Insufficient data to determine if 8EQ's debt to equity ratio has reduced over the past 5 years.
Balance Sheet
Cash Runway Analysis
For companies that have on average been loss-making in the past, we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: Whilst unprofitable 8EQ has sufficient cash runway for more than 3 years if it maintains its current positive free cash flow level.
Forecast Cash Runway: 8EQ is unprofitable but has sufficient cash runway for more than 3 years, even with free cash flow being positive and shrinking by 31.2% per year.